European Drug Shortages Hit Record Levels: Norway and Generics Most Affected
核心洞察
European pharmaceutical markets face unprecedented drug shortages in 2023-2024, driven by inflation, high operating costs, and rigid pricing systems, with Norway reporting 58% of total shortages across seven analyzed countries.
Generic medications are experiencing the most severe supply disruptions, with 11% of affected active ingredients reporting shortages in four or more European markets simultaneously.
Nervous system medications, particularly analgesics and psycholeptics, represent 25% of shortage-affected products, prompting various European governments to implement flexible pricing policies and regulatory adjustments.
The European pharmaceutical landscape is grappling with an unprecedented surge in drug shortages, with Norway emerging as the most severely affected market among seven analyzed European countries. The crisis, which began in 2023, has intensified into 2024, primarily driven by inflationary pressures and escalating operational costs.
Geographic Distribution and Scope of Shortages
Analysis across seven European markets - Belgium, Austria, Italy, Norway, Portugal, Slovenia, and Spain - reveals that Norway accounts for 58% of reported shortages, followed by Slovenia at 20% and Italy at 10%. The crisis encompasses 17,250 medication packs representing 1,278 active ingredients, with 11% of these ingredients experiencing shortages across four or more markets simultaneously.
Generic Medications Bear the Brunt
Generic medications have emerged as the most vulnerable sector in this supply crisis. Elisabeth Stampa, president of the Medicines for Europe (搜索) trade association, warns that generic drug shortages will persist unless pricing structures are adjusted to reflect inflation-driven cost increases. Norway presents a unique case, with 31% of shortages affecting branded, on-patent medicines, including key products like Aranesp, Minirin, and Oxis (搜索).
Impact on Critical Therapeutic Areas
The nervous system medication category has been particularly hard hit, accounting for 25% of all shortage-affected products. Analgesics and psycholeptics, crucial for managing pain, schizophrenia (搜索), and epilepsy (搜索), are among the most impacted therapeutic classes. Manufacturing challenges and cross-border sourcing have exacerbated these shortages.
Multi-Brand Impact and Reimbursement Status
The crisis has shown significant cross-brand effects, with Portugal experiencing the highest percentage (50%) of shortages affecting multiple brands of the same active ingredient, followed by Italy (44%) and Slovenia (29%). Notably, 51% of affected products are non-reimbursed medications, though this distribution varies by country, with Italy and Norway reporting more shortages among reimbursed products.
Market Response and Policy Adaptations
European governments are implementing various measures to address these shortages. Responses include increasing price caps, adjusting exchange rates, relaxing procurement rules, and expanding risk-sharing agreements. The extent and nature of these interventions largely depend on each country's perceived threat level, domestic pharmaceutical industry strength, and financial capabilities.
Special Focus: Norway's Market Challenges
Norway's disproportionate share of shortages can be attributed to its restrictive pricing policies and unfavorable exchange rates. These factors, combined with increased manufacturing costs in 2023, have made it financially unsustainable for many products to remain in the Norwegian market. The situation has led to specific interventions, such as the reimbursement of Novo Nordisk's Rybelsus to address semaglutide shortages.
Future Outlook
The ongoing crisis signals a need for systematic changes in European pharmaceutical pricing and supply chain management. As manufacturers continue to face cost pressures and market access challenges, the effectiveness of current policy adjustments will be crucial in determining the trajectory of drug availability across European markets.